Ohlan, R. | bioRxiv Science

bioRxiv2026

GEM-GPT Enables Personalized Cell Type-Resolved Therapeutic Design for Systems Pharmacology

Generative AI is transforming drug discovery, yet most approaches follow one-drug-one-target paradigms ill-suited to the heterogeneity of chronic, systemic diseases. Systems pharmacology offers an alternative, but generative tools designed for it remain scarce. We introduce GEM-GPT, a transcriptomics-guided framework that generates personalized therapeutic candidate molecules intended to shift cell type-specific disease states toward healthy phenotypes. GEM-GPT uses a biology-inspired deep fusion architecture that couples a single-cell RNA-sequencing foundation model with a molecular GPT, modeling cell type-specific chemical-gene interactions throughout molecule generation rather than through fixed conditioning. Across bulk and single-cell chemical perturbations and CRISPR knock-out signatures, GEM-GPT outperforms state-of-the-art baselines, produces cell type-resolved molecules, and generalizes to unseen cellular contexts. In a case study on opioid use disorder (OUD), it generates novel candidates, recovers FDA-approved OUD-related drugs absent from training, and yields predicted binders to OUD-related targets. GEM-GPT bridges single-cell omics and molecular generation for personalized, cell-type-resolved, systems-aware therapeutic design.

pharmacology and toxicology↗

bioRxiv2025

MolGene-E: Inverse Molecular Design to Modulate Single Cell Transcriptomics

Designing drugs that can restore a diseased cell to its healthy state is an emerging approach in systems pharmacology to address medical needs that conventional target-based drug discovery paradigms have failed to meet. Single-cell transcriptomics can comprehensively map the differences between diseased and healthy cellular states, making it a valuable technique for systems pharmacology. However, single-cell omics data is noisy, heterogeneous, scarce, and high-dimensional. As a result, no machine learning methods currently exist to use single-cell omics data to design new drug molecules. We have developed a new deep generative framework named MolGene-E to tackle this challenge. MolGene-E combines two novel models: 1) a cross-modal model that can harmonize and denoise chemical-perturbed bulk and single-cell transcriptomics data, and 2) a contrastive learning-based generative model that can generate new molecules based on the transcriptomics data. MolGene-E consistently outper-forms baseline methods in generating high-quality, hit-like molecules on gene expression profiles from two evaluation settings: CRISPR knock-out perturbation profiles from L1000toRNAseq dataset, and single-cell gene expression profiles from Sciplex-3 dataset, both in zero-shot molecule generation setting. This superior performance is demonstrated across diverse de novo molecule generation metrics. Extensive evaluations demonstrate that MolGene-E achieves state-of-the-art performance for zero-shot molecular generations. This makes MolGene-E a potentially powerful new tool for drug discovery.

bioinformatics↗